SynAct Pharma
SYNACT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008241491 (+1 more)
- LEI:
- 549300RRYIEFEQ72N546
- Country:
- Sweden
- Address:
- Scheelevägen 2, 223 63 Lund
- Website:
- https://synactpharma.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects, so that patients can achieve immune balance and live beyond their inflammation. AP1189, our product candidate selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression that is associated with most of the available anti-inflammatory therapies. These immunosuppressive approaches can lead to opportunistic infections and other serious side effects.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for SynAct Pharma.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
|
Swedish | 62.1 KB | |
| 2025-08-15 08:55 |
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
|
English | 61.3 KB | |
| 2025-08-05 11:34 |
Major Shareholding Notification
|
Swedish | 10.6 KB | |
| 2025-07-31 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 59.6 KB | |
| 2025-07-31 18:00 |
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
|
English | 59.3 KB | |
| 2025-07-15 22:13 |
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
|
English | 61.8 KB | |
| 2025-07-15 22:13 |
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
|
Swedish | 62.8 KB | |
| 2025-07-15 21:00 |
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
|
Swedish | 62.2 KB | |
| 2025-07-15 21:00 |
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after conversion of warrants
|
English | 61.3 KB | |
| 2025-07-11 13:28 |
Major Shareholding Notification
|
Swedish | 10.6 KB | |
| 2025-06-30 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 59.0 KB | |
| 2025-06-30 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
|
English | 59.2 KB | |
| 2025-06-13 10:18 |
Major Shareholding Notification
|
Swedish | 10.6 KB | |
| 2025-06-04 08:50 |
Share Issue/Capital Change
SynAct Pharma AB genomför en riktad nyemission om 37 MSEK och förlänger sin fin…
|
Swedish | 77.4 KB | |
| 2025-06-04 08:50 |
Share Issue/Capital Change
SynAct Pharma AB carries out a directed share issue of SEK 37 million and exten…
|
English | 75.9 KB |
Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SynAct Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-30 | Anders Kronborg | Other | Buy | 28,902 | 250,002.30 SEK |
| 2024-06-01 | Björn Westberg | Other | Other | 516,205 | N/A |
| 2024-04-30 | Jeppe Øvlesen | Other | Other | 58,139 | 499,995.40 SEK |
| 2024-04-30 | Anders Kronborg | Other | Other | 34,883 | 299,993.80 SEK |
| 2024-03-21 | Jeppe Øvlesen | Other | Other | 245,870 | 1,696,503.00 SEK |
| 2023-11-09 | Thomas Jonassen | Other | Other | 3,531,644 | 22,072,775.00 SEK |
| 2023-11-09 | Thomas Jonass | Other | Other | 2,161,225 | 13,507,656.25 SEK |
| 2023-01-16 | Jeppe Øvlesen | Other | Other | 1,161,777 | 72,727,240.20 SEK |
| 2023-01-16 | James Knight | Other | Other | 77,452 | 4,848,495.20 SEK |
| 2023-01-16 | Thomas Boesen | Other | Other | 32,917 | 2,060,604.20 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
BioPorto | Denmark | BIOPOR | |
|
BioSenic SA | Belgium | BIOS | |
|
Biosergen AB | Sweden | BIOSGN | |
|
BIOTECH | Spain | BST | |
|
Biotest AG | Germany | BIO3 | |
|
Bioton S.A. | Poland | BIO | |
|
Bioversys N | Switzerland | BIOV | |
|
Biovica International B | Sweden | BIOVIC | |
|
Bonus BioGroup Ltd. | Israel | BONS | |
|
BRAIN Biotech AG | Germany | BNN |